profit from every $100 of sales.
$0$100
GlucoTrack
$0.22-9.67% today
-99.9% in 1 year
1-year low $0.221-year high $204.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What GlucoTrack sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$19.4 million of profit last year.
SalesProfit
GlucoTrack vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| GlucoTrack | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads GlucoTrack's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -4 | -7 | -15 | -16 | |
| -4 | -7 | -15 | -16 | |
| -4 | -7 | -23 | -19 | |
| -1,740.00 | -2,050.80 | -4,106.00 | -31.22 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2 | 5 | 6 | 8 |
| Cash | 2 | 4 | 6 | 7 |
| Total debt | 0 | 0 | 0 | 3 |
| Total liabilities | 1 | 2 | 19 | 5 |
| 1 | 3 | -13 | 3 | |
| 0 | 0 | 0 | 1 | |
| -245.7% | -165.2% | – | -202.6% | |
| -360.6% | -222.0% | 173.8% | -685.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | -7 | -12 | -15 | |
| 0 | – | 0 | 0 | |
| -4 | -7 | -13 | -15 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 0.3×
- –
- –
- 0.4×
- -5,973.9%
- -7,552.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -520.2%
- -219.2%
- -393.3%
- -247.4%
- -525.0%
- –
Growth
- –
- –
- −21.8%
- –
- +55.5%
Financial health
- 0.4×
- 0.01
- 0.4%
- -128.7×
- 1.61
- 1.61
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 883
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -2.65 | – | – |
| Mar 30, 2026 | -3.98 | – | – |
| Nov 13, 2025 | -4.64 | – | – |
| Aug 14, 2025 | -9.62 | – | – |
| May 14, 2025 | -20.36 | – | – |
| Mar 27, 2025 | 10.00 | – | – |
| Nov 14, 2024 | -1,089.82 | – | – |
| Aug 13, 2024 | -982.04 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
67Pass
Philip Fisher
32No pass
Peter Lynch
60Pass
Joel Greenblatt
100Pass
Charlie Munger
40No pass
Terry Smith
37No pass
Questions about GlucoTrack
Is GlucoTrack a good stock to buy?
A business with weak numbers that is not profitable yet. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the GlucoTrack AI analysis
What does GlucoTrack do?
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It is in Medical - Instruments & Supplies.
Does GlucoTrack pay a dividend?
No. GlucoTrack does not pay a dividend at the moment.
Is GlucoTrack stock halal?
No. GlucoTrack does not pass our halal screen: its debt is 1,342% of its market value, at or above the 33% limit. How we check
How has GlucoTrack stock done over the past year?
Down 99.9% over the past twelve months, to $0.22. It traded between $0.22 and $204.00 and is 99.9% below its high.
Who are GlucoTrack's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with GlucoTrack's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.